Terms ending in 2039
Bayer Pharma Aktiengesellschaft
Every in-force patent on Bayer Pharma Aktiengesellschaft's record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,524,944 | 2-Phenylpyrimidine-4-Carboxamides as Ahr Inhibitors In force · High confidence | Deutsches Krebsforschungszentrum | In force | High confidence | |
| US 10,828,310 | Reducing the Risk of Cardiovascular Events In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 11,478,451 | Macrocyclic Chlorine Substituted Indole Derivatives In force · High confidence | Bayer Aktiengesellschaft and Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 11,660,351 | Antibody Drug Conjugates (ADCS) Having Enzymatically Cleavable Groups In force · High confidence | Bayer Aktiengesellschaft and Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 11,365,179 | Method for the Preparation of a 2,4,5-Trisubstituted 1,2,4-Triazolone In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 12,448,381 | Method for the Preparation of (4S)-4-(4-Cyano-2-Methoxyphenyl)-5-Ethoxy-2,8-Dimethyl-1,4-Dihydro-1-6-Naphthyridine-3-Carbox-AMIDE by Racemate Separation by Means of Diastereomeric Tartaric Acid Esters In force · High confidence | Bayer Aktiengesellschaft and Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 11,542,245 | Preparative Process In force · High confidence | Bayer Aktiengesellschaft and Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 11,685,714 | Prodrugs of Cytotoxic Active Agents Having Enzymatically Cleavable Groups In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 11,655,297 | ILDR2 Antagonists and Combinations Thereof In force · High confidence | Compugen Ltd. | In force | High confidence | |
| US 11,701,347 | Use of 5-Fluoro-4-(4-Fluoro-2-Methoxyphenyl)-N-{4-[(S-METHYLSULFONIMIDOYL)METHYL]PYRIDIN-2-YL}PYRIDIN-2-Amine for Treating Diffuse Large B-Cell Lymphoma In force · High confidence | Bayer Aktiengesellschaft and Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| 4 more term ends in 2039 · Pro | |||||
10 of 14 patents shown. Soonest term end first, then patent number.
Pro members see all 14.
11 of these are in force and held by Bayer Pharma Aktiengesellschaft.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.